newsfilter
← Latest News
Business Wire·

BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines

Total proceeds, assuming no redemptions, are expected to be $450 million, combining funds held in the Helix Acquisition Corp. II trust account and a private investment in public equity (PIPE) financing Leading